Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

92 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study.
Introna M, Borleri G, Conti E, Franceschetti M, Barbui AM, Broady R, Dander E, Gaipa G, D'Amico G, Biagi E, Parma M, Pogliani EM, Spinelli O, Baronciani D, Grassi A, Golay J, Barbui T, Biondi A, Rambaldi A. Introna M, et al. Among authors: barbui t, barbui am. Haematologica. 2007 Jul;92(7):952-9. doi: 10.3324/haematol.11132. Haematologica. 2007. PMID: 17606446 Free article. Clinical Trial.
The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells.
Golay J, Cuppini L, Leoni F, Micò C, Barbui V, Domenghini M, Lombardi L, Neri A, Barbui AM, Salvi A, Pozzi P, Porro G, Pagani P, Fossati G, Mascagni P, Introna M, Rambaldi A. Golay J, et al. Among authors: barbui v, barbui am. Leukemia. 2007 Sep;21(9):1892-900. doi: 10.1038/sj.leu.2404860. Epub 2007 Jul 19. Leukemia. 2007. PMID: 17637810
Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma.
Tarella C, Passera R, Magni M, Benedetti F, Rossi A, Gueli A, Patti C, Parvis G, Ciceri F, Gallamini A, Cortelazzo S, Zoli V, Corradini P, Carobbio A, Mulé A, Bosa M, Barbui A, Di Nicola M, Sorio M, Caracciolo D, Gianni AM, Rambaldi A. Tarella C, et al. Among authors: barbui a. J Clin Oncol. 2011 Mar 1;29(7):814-24. doi: 10.1200/JCO.2010.28.9777. Epub 2010 Dec 28. J Clin Oncol. 2011. PMID: 21189387
Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study.
Carella AM, de Souza CA, Luminari S, Marcheselli L, Chiappella A, di Rocco A, Cesaretti M, Rossi A, Rigacci L, Gaidano G, Merli F, Spina M, Stelitano C, Hohaus S, Barbui A, Puccini B, Miranda EC, Guida A, Federico M. Carella AM, et al. Among authors: barbui a. Leuk Lymphoma. 2013 Jan;54(1):53-7. doi: 10.3109/10428194.2012.691482. Epub 2012 Sep 28. Leuk Lymphoma. 2013. PMID: 22712840
The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy.
Rambaldi A, Boschini C, Gritti G, Delaini F, Oldani E, Rossi A, Barbui AM, Caracciolo D, Ladetto M, Gueli A, De Crescenzo A, Passera R, Devizzi L, Patti C, Gianni AM, Tarella C. Rambaldi A, et al. Among authors: barbui am. Am J Hematol. 2013 Dec;88(12):1062-7. doi: 10.1002/ajh.23566. Epub 2013 Sep 30. Am J Hematol. 2013. PMID: 23940056 Free article.
92 results